About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05351515

Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography

Obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) are both common diseases related to metabolic diseases with potential cardiovascular consequences and liver complications re...

Lead sponsor: Chinese University of Hong Kong•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Ken KP Chan

CONTACT

+852 35052211 chankapang@cuhk.edu.hk

Sponsors

Lead Sponsor

Chinese University of Hong Kong

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•aged 18 years or more

Exclusion Criteria

•underlying cause of liver disease
•history of excessive alcoholic consumption (more than 30 g/day for men and 20 g/day for women)
•secondary causes of hepatic steatosis (such as chronic use of systemic corticosteroids)
•positive hepatitis B surface antigen, anti-hepatitis C virus antibody, or histological evidence of other concomitant chronic liver diseases.

Related studies

RECRUITINGPhase 1

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

NCT03860233 · Sleep Apnea, Sleep Apnea, Obstructive

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

NCT07265544 · Liver Neoplasm, HBV Infection, and more

RECRUITINGPhase 1

Effect of Insulin Lowering on Lipogenesis

NCT07403604 · Hyperinsulinemia, Insulin Resistance, and more

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784 · MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 30, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment1,000

Start dateApr 2022

Last updatedAug 30, 2023

Condition

Sleep Apnea, Obstructive Fatty Liver

Locations shown

Chinese University of Hong Kong

Hong Kong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 30, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions